An expansion of Tregs was observed in the tumor with low dose IL-2, but not with intermediate or high dose IL-2, possibly owing to the fact that there is abundant expression of high-affinity IL-2 trimeric (CD25–CD122–CD132) receptors on Tregs as compared to effector T cells (11). This evidence concerns the gene IL2RB and neoplasm.